Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of ...
Moderna (MRNA) traded higher in the premarket on Thursday after the Cambridge, Massachusetts-based biotech exceeded Street ...
The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...
A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...
Moderna (MRNA) and Merck (MRK) reported data regarding their cutting-edge mRNA-based skin cancer regimen that includes the former's cancer vaccine, MRNA-4157. The companies recently reported promising ...
Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on ...
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent ...
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its investigational mRNA therapeutics have been accepted for presentation at the ...
Vaccine experts told STAT that the data Moderna released May 18 from its phase I vaccine trial isn’t enough to show whether or not the vaccine will be effective. Moderna released data from an early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback